Incidence of precancerous cervical lesions decreasing among young women
the ONA take:
According to a new study published in the journal Cancer, researchers have found that the incidence of high-grade cervical lesions in young women has significantly decreased, but the declines were likely due to reduced screening.
Cervical intraepithelial neoplasia grade 2, 3, and adenocarcinoma in situ (CIN2+) lesions can be monitored as early indicators of the effect of human papillomavirus (HPV) vaccines.
For the study, researchers identified over 9,000 cases of CIN2+ among patients aged 18 to 39 years in California, Connecticut, New York, and Oregon.
Researchers found that from 2008 to 2012, the rates of CIN2+ significantly decreased among women aged 18 to 20 years in all four states and among 21- to 29-year-old women in Connecticut and New York.
Researchers found that screening rates also declined during that time period, suggesting that the decline in these cervical lesions is most likely due to fewer screenings, but could potentially be an effect of vaccination as well.
Incidence of high-grade cervical lesions in young women has significantly decreased, but the declines were likely due to reduced screening.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|